Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be announcing earnings results tomorrow morning. Here’s what investors should know. Bristol-Myers Squibb beat analysts’ revenue ...

Shares of Bristol-Myers Squibb (NYSE:BMY) traded higher in the premarket on Thursday after the pharma giant beat Street forecasts with its Q1 2025 results and raised its full-year outlook ...

Biotech giant Bristol Myers Squibb BMY was down on data from the schizophrenia study while Regeneron REGN was in the spotlight on updates on key drugs. Bristol Myers announced disappointing top ...

Bristol-Myers Squibb Company is undervalued, trading 30% below its intrinsic value, with a low price-to-free-cash-flow ratio indicating a strong buying opportunity. In the first quarter ...

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Bristol-Myers Squibb (BMY – Research Report). The company’s shares closed yesterday at $49.82.

Bristol Myers Squibb (BMY) came out with quarterly earnings of $1.80 per share, beating the Zacks Consensus Estimate of $1.51 per share. This compares to loss of $4.40 per share a year ago.

PRINCETON, N.J. (AP) — PRINCETON, N.J. (AP) — Bristol Myers Squibb Co. (BMY) on Thursday reported first-quarter net income of $2.46 billion, after reporting a loss in the same period a year ...

In a report released yesterday, Courtney Breen from Bernstein maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report), with a price target of $62.00. The company’s shares ...